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deprivation in glioblastoma evoked specific changes in 
actin assembly, decreased β-actin filament content, and 
affected its N-terminal arginylation. We suggest that 
alterations in organization of β-actin resulted from a 
decrease of its arginylation could be responsible for the 
observed effects of arginine deprivation on cell invasive-
ness and migration. Our data indicate that arginine dep-
rivation-based treatment strategies could inhibit, at least 
transiently, the invasion process of highly malignant brain 
tumors and may have a potential for combination therapy 
to extend overall patient survival.
Keywords Amino acid deprivation · Actin cytoskeleton · 
Actin arginylation · Cancer · Invasiveness · Cell migration
Introduction
Tumor cells often exhibit metabolic defects in amino acid 
biosynthesis and, concomitantly, hypersensitivity to depri-
vation of certain amino acids. This feature was exploited to 
develop enzymotherapies based on single amino acid depri-
vation, such as asparagine, methionine and arginine (Covini 
et al. 2012; Agrawal et al. 2012; Delage et al. 2010). Still, 
the molecular mechanisms determining the sensitivity of 
malignant cells to single amino acid deficiency remain 
a subject of ongoing investigations (Bobak et al. 2010; 
Morrow et al. 2013).
Arginine is a semi-essential amino acid in humans and 
its physiological level is maintained through protein deg-
radation, endogenous synthesis and food intake (Morris 
2007). It has been established that an increased dependence 
on exogenous arginine is typical for many malignant tumor 
cells, both in vitro and in vivo (Scott et al. 2000; Wheat-
ley et al. 2005; Feun et al. 2008). Also, a growing number 
Abstract A deficit of exogenous arginine affects growth 
and viability of numerous cancer cells. Although arginine 
deprivation-based strategy is currently undergoing clini-
cal trials, molecular mechanisms of tumor cells’ response 
to arginine deprivation are not yet elucidated. We have 
examined effects of arginine starvation on cell motility, 
adhesion and invasiveness as well as on actin cytoskeleton 
organization of human glioblastoma cells. We observed 
for the first time that arginine, but not lysine, starva-
tion affected cell morphology, significantly inhibited 
their motility and invasiveness, and impaired adhesion. 
No effects on glia cells were observed. Also, arginine 
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of tumors is being identified as deficient in arginine ana-
bolic enzyme argininosuccinate synthetase (ASS) and, thus 
auxotrophic for arginine (Allen et al. 2014; Delage et al. 
2010; Dillon et al. 2004). Growth of such tumors can be 
controlled by the treatment with two arginine degrading 
recombinant enzymes, human arginase I or bacterial argi-
nine deiminase; both currently undergoing phase I/II clini-
cal trials (Glazer et al. 2010; Yang et al. 2010; Yau et al. 
2013).
The elevated tumor cell sensitivity to arginine depri-
vation may result from the complex nature of arginine 
metabolism and its impact on a number of metabolic and 
signaling pathways. We recently showed that in vitro 
arginine is essential for the growth of malignant cells of 
different organ origin but the levels of intrinsic arginine 
metabolic enzymes do not determine tumor cell response 
to arginine-deprivation stress (Bobak et al. 2010). We also 
observed that the sensitivity of tumor cells to arginine star-
vation dramatically decreased in 3-D spheroids relative 
to corresponding monolayer cultures but some effects are 
qualitatively maintained (Vynnytska-Myronovska et al. 
2012).
Although arginine deprivation-based enzymotherapy is 
at the developmental stage, it clearly bears a potential as 
an efficient, selective and relatively non-toxic approach 
against highly malignant ASS-negative tumors, e.g. blad-
der (Allen et al. 2014), melanoma (Yoon et al. 2013), pan-
creatic (Bowles et al. 2008), prostate (Kim et al. 2009), 
renal (Yoon et al. 2007) carcinomas and glioblastomas 
(Syed et al. 2013). For further optimization and develop-
ment of rational combinational approaches, molecular 
signaling mechanisms governing tumor cell response to 
arginine deprivation have to be elucidated. Another thera-
peutically highly relevant question is whether and how 
arginine deprivation affects tumor cells motility and inva-
siveness. This is of particular interest in glioblastomas, 
the most malignant primary brain tumors that are hardly 
amenable to conventional therapies because of their highly 
motile and invasive nature (Brandes 2007). No curative 
treatment is available for these patients and overall sur-
vival time is rather short thus new treatment strategies are 
urgently needed.
In this report, we addressed this problem for the first 
time using three human glioblastoma cell lines as well 
as organotypic brain slices as experimental models. We 
describe the specific effects of arginine withdrawal on 
glioblastoma cell morphology and demonstrate that lack 
of arginine but not lysine profoundly impairs glioblastoma 
motility, adhesion and invasiveness. We propose that these 
effects could result from specific alterations in the actin 
cytoskeleton organization evoked by a deficit in β-actin 
arginylation.
Materials and methods
Cell culture and transfection
Human glioblastoma U251 MG (U251) and U87 MG (U87) 
cell lines were purchased from CLS Cell Lines Service 
(Germany) and monitored for correct genetic profile via 
microsatellite analyses according to a protocol described 
earlier (Peickert et al. 2012). LN-229 glioblastoma cells 
were from Prof. Marta Mia˛czyn´ska from the International 
Institute of Molecular and Cell Biology in Warsaw, Poland. 
Cells were cultured at 37 °C and 5 % CO2 in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 
GlutaMAX-1, 10 % fetal bovine serum (FBS), 100 U/mL 
penicillin and 100 U/mL streptomycin (Gibco Live Tech-
nologies, USA). For most experiments, a formulated amino 
acid-free DMEM (Sigma-Aldrich, USA) was used. In order 
to prepare arginine- (-Arg) or lysine-free (-Lys) condi-
tions, the medium was supplemented with all the amino 
acids except of arginine or lysine, respectively. A complete 
(control) medium was obtained by supplementation with 
all the amino acids (0.4 mM for arginine, and 0.8 mM for 
lysine and leucine). -Arg, -Lys and control media were sup-
plemented with 5 % dialyzed FBS (Sigma-Aldrich, USA), 
lacking small molecules such as amino acids. U251 cells 
cultivated in the control medium were transfected with 
pmaxGFP plasmid using Nucleofection™ technology 
(Lonza Group Ltd., Switzerland).
Culture conditions of astrocytes
Primary cultures of neonatal astrocytes were isolated 
from forebrains of 1-day-old Wistar rat pups as previ-
ously described (Zawadzka and Kaminska 2003), seeded 
on cover slips immediately after isolation, and cultured 
for 48 h in the control, -Arg or -Lys media, as described 
above. Housing and sacrificing procedures were performed 
in compliance with the European Communities Council 
Directive of 24 November 1986 (86/609/EEC).
Brain organotypic slice culture
Horizontal slices (300-μm) were prepared from brains of 
neonatal (E13) and adult (6-month-old) female rats and cul-
tured as described by Stoppini et al. (1991). Housing and 
sacrificing procedures were performed as described above.
Growth assay
Cells (105) were grown in the tested conditions and counted 
after 48 and 96 h using manual cell counter (Scepter 2.0, 
Millipore, USA), after prior trypsinization with 0.25 % 
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trypsin–EDTA (1×) solution (Gibco Life Technologies, 
USA).
MTS viability assay
On day zero, dissociated single cell suspensions were 
seeded in two triplicate sets of 96-well microtiter plates 
(103 cells/well). On day 1, the supernatant of the first set 
of cells was replaced with fresh media and the amount of 
viable cells was determined after 48, 96 or 144 h using 
a colorimetric cell viability assay (CellTiter 96 AQue-
ous Non-Radioactive Cell Proliferation Assay from Pro-
mega, USA). The second set was exposed to -Arg or -Lys 
medium for 48, 96 or 144 h, and then cultured in com-
plete medium for additional 48-h period to assess growth 
restoration, followed by the viability assay performed as 
described above.
Immunolocalization
Cells were treated as described in (Majewski et al. 2011), 
and then stained with Alexa 488-conjugated phalloidin 
to visualize the actin cytoskeleton. Staining for adhesive 
structure markers was also performed using monoclonal 
antibody against vinculin (Sigma-Aldrich, USA) and poly-
clonal antibody against talin (Santa Cruz, USA) at a dilu-
tion of 1:40. For negative controls, primary antibody was 
omitted. Images were collected with the Leica TCS SP5 
confocal laser scanning microscope equipped with a 63× 
HCX oil CS UV 1.4 oil-immersion objective.
Scanning electron microscopy (SEM)
For SEM, U251 cells were fixed in 3 % glutaraldehyde in 
0.2 M phosphate buffer for 30 min at room temperature fol-
lowed by 1 % OsO4 for 1 h, and then dehydrated through 
graded series of ethanol and acetone, dried by the CO2 criti-
cal point method and coated with a thin layer of carbon and 
gold. Samples were examined using a Jeol JEM-1200EX 
electron microscope with ASID 19 scanning attachment, 
operating at 80 kV.
Random motility assay
Random motility was assessed by time-lapse microscopy as 
detailed previously (Majewski et al. 2011). Cells were pho-
tographed every 10 min for up to 36 h. At least 10 cells of 
each experimental condition were tracked (cells undergo-
ing division or apoptosis were excluded). The tracks (reori-
ented to zero in migration traces) and velocity were calcu-
lated using the Metamorph software (Molecular Devices, 
USA).
Transwell migration assay
The assay, based on chemotactic directional migration, was 
performed in 24-well Transwell inserts using 6.5-mm diam-
eter polycarbonate filters with 8-µm pores, coated for 10 h 
with 30 μg/mL of type I collagen (Sigma-Aldrich, USA) 
as described in (Albini et al. 1987). Cells (104) were placed 
in serum-free media into the upper chamber and allowed 
to migrate through the filter to the lower chamber contain-
ing DMEM media supplemented with 10 % FBS. After 6 h, 
non-migrated cells were removed from the upper chamber 
using a cotton swab. The cells, which passed through the 
filter and attached to its trans side were stained with 2 % 
crystal violet after fixation with 4 % formaldehyde. Filters 
were photographed and the number of migrated cells was 
counted.
Invasiveness test
The effects of arginine deprivation on cell invasiveness 
were assessed using 8.0-μm pore size Matrigel-coated 
invasion chamber inserts (BD BioCoat, USA). Cells were 
maintained as described above and were allowed to invade 
through the filter for 24 h.
Also, GFP-expressing U251 cells were placed on brain 
organotypic slices and after 24 h the presence of fluores-
cent cells within a slice was examined after fixation with 
4 % paraformaldehyde by means of confocal microscopy. 
For quantification, at least three view areas of each exam-
ined conditions of both neonatal and adult brain slices were 
analyzed.
Analysis of cell adhesion
Cell adhesion to the glass surface was assessed by counting 
the number of vinculin-stained structures in twenty cells 
from each experimental condition. For analysis of cell–cell 
adhesion, the equal number of examined cells was plated 
on soft agar. The number and size of cell aggregates (with 
respect to the seeded cell number) were evaluated for each 
experimental condition.
Western blotting
Cell lysates were separated by 12 % SDS-PAGE followed 
by a transfer to nitrocellulose membrane (as in 22). Actin 
and tubulin were detected by monoclonal antibodies against 
β-actin and β-tubulin (Sigma-Aldrich, USA), and against 
γ-actin (Millipore, USA), all diluted at 1:1,000. Talin and 
vinculin were detected with the respective monoclonal and 
polyclonal antibodies (see above) at 1:1,000 dilution. Also, 
CD44 was detected with anti-CD44 monoclonal antibody 
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(R&D System, USA) and E-cadherin was detected with 
anti-M-cadherin antibody (BD Biosciences, UK), both at 
1:1,000 dilution. Anti-mouse antibody and anti-rabbit anti-
body conjugated with horse radish peroxidase were applied 
(at 1:10,000 dilution) for detection using ECL system 
Pierce, USA). Protein concentration was determined by 
Bio-Rad protein assay reagent (Bio-Rad, USA).
Analysis of actin organization by sedimentation assay
Cell lysates (considered as “totals” in the course of the 
analysis) were incubated for 1 h at 4 °C in the presence or 
absence of 0.04 mg/mL phalloidin (Sigma, USA). After 
1-h ultracentrifugation at 150,000×g, the aliquots of super-
natant and pellet fractions were analyzed by SDS-PAGE 
and Western blot to assess the amount of actin (β- and 
γ-isoforms) and β-tubulin. Developed blots were photo-
graphed and analyzed using the G:Box system equipped 
with GeneSnap and GeneTools software.
Flow cytometric analysis of filamentous actin content
Harvested cells (105) were extensively washed with ice-
cold PBS and fixed in 70 % ethanol. For the analysis, the 
single cell suspensions were resuspended in PBS solution 
containing extraction buffer (0.2 M Na2HPO4, 0.1 M citric 
acid and 50 µg/mL RNase A (Invitrogen, USA) and incu-
bated with Alexa488-conjugated phalloidin (0.2 U). After 
exhaustive washes with PBS, the fluorescence signal cor-
responding to F-actin was measured by flow cytometry 
(FACS Calibur) using CellQuest Software; 10,000 events 
were analyzed for each sample.
2D electrophoresis
2D electrophoresis was performed as described previously 
(Bregier et al. 2013). Cell lysates were cleared with Bio-
Rad Protein Precipitation Kit as per manufacturer’s pro-
tocol. The protein mixtures were applied to ReadyStrip™ 
IPG 7 cm strips, pH 4–7 (linear) (Bio-Rad, USA) and then 
isoelectrically focused using a PROTEAN IEF cell System 
(Bio-Rad) followed by 12 % SDS-PAGE and a transfer 
onto nitrocellulose membrane and Western blotting. Actin 
isoelectric pattern in the lysates was determined using rab-
bit polyclonal anti-actin antibodies (Sigma-Aldrich, USA).
Identification of arginylated β-actin by tandem mass 
spectrometry
For the analysis of samples obtained in the deprivation 
experiments, 40 µg of protein from each sample were sep-
arated in 12 % SDS-PAGE and silver stained as described 
in (Shevchenko et al. 1996). The bands corresponding to 
actin were excised from the gels, destained and digested 
with trypsin according to (Shevchenko et al. 2006). Pep-
tides were analyzed by nanoUPLC-tandem mass spectrom-
etry employing Acquity nanoUPLC coupled with Synapt 
G2 HDMS Q-TOF mass spectrometer (Waters, USA), fit-
ted with a nanospray source and working in MS^E mode 
under default parameters (Drozak et al. 2013). To identify 
arginylated β-actin, all human protein sequences down-
loaded from UniProt database were supplemented with 
the sequences of arginylated β-actin on Arg2 and Arg3 
randomized, and used as a databank of the MS/MS soft-
ware. Mass chromatograms obtained from control and 
deprived experimental variants samples allowed us estab-
lish changes in β-actin arginylation extent. First, the chro-
matograms for single ion of arginylated peptide were 
integrated, giving a measure of the amount of arginylated 
peptide in each chromatographic run. However, to estab-
lish the arginylation extent, in addition to the measure of 
arginylated peptide present in the run, a measure of the 
amount of β-actin in the injected sample is also needed 
as a reference point. A relative measure was obtained by 
comparing the peak areas of five randomly chosen pep-
tides from be β-actin on respective single ion chromato-
grams. The peak areas on chromatograms of samples from 
deprivation variants were divided by the areas of respec-
tive peaks on chromatograms from control samples and the 
obtained values were averaged giving a relative measure 
of the total amount of digested β-actin injected as a factor 
of the amount injected from the control sample. This fac-
tor was used to correct the peak areas of the arginylated 
peptide in the injection of samples coming from depriva-
tion experiments, to the values expected if the amount of 
β-actin in each run was the same and to compare the val-
ues. The peak area of arginylated peptide in control was 
set to one and the values -Arg and -Lys were proportion-
ally adjusted. Such an approach not only provides a com-
mon point to which a peak area of the arginylated peptide 
can by referred, but also compensates for possible fluctua-
tions in the ionization efficiency, between different runs. 
The single ion chromatograms for selected peptides were 
filtered from TIC chromatogram by the software. Peptides 
used as reference were fragments flanked by the following 
amino acids in the β-actin sequence (in parentheses mass 
of MH+ ion): 19–28 (976.45), 40–44 in source fragment 
(553.26), 85–95 (1,515.75), 216–238 with carbamido-
methyl modification on cysteine (2,550.17) and 239–254 
(1,790.89).
Statistical analysis
Data are presented as mean ± SD; all p values were calcu-
lated by two-sided Student’s t test. The difference was con-
sidered to be statistically significant at the level of p < 0.05.
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Results
Arginine deprivation affects cell viability
First, we evaluated whether growth and viability of human 
U251 and U87 glioblastoma cells were affected by arginine 
deprivation in comparison with deprivation of lysine, an 
essential and also positively charged amino acid.
As expected, deprivation of arginine or lysine abrogated 
growth of both cell lines (Fig. 1a), indicating that both 
amino acids are essential in vitro. Of note, proliferation of 
both glioblastoma cell lines was not rescued in ornithine-, 
and only partially restored in citrulline-containing arginine-
deficient medium, indicating the impairment of arginine 
biosynthesis and their full arginine auxotrophy in vitro (not 
shown).
Viability of -Arg cells was decreased by ~50 % with 
respect to control cells already after 48 h and remained on 
this level up to 144 h. Importantly, growth and viability of 
U251 cells was restored nearly to the level of control cells 
when cells were exposed for an additional 48 h to control 
medium, indicating reversibility of the inhibitory effect 
(Fig. 1b). Viability of -Lys cells was decreasing gradually 
during the time course of the experiment (up to ~40 %), 
and was only partially restored upon lysine re-supplemen-
tation (up to ~70 %).
Importantly, no induction of apoptosis was found in 
-Arg and -Lys cells as judged by the absence of activated 
form of PARP and a flow cytometric apoptosis test (Elec-
tronic Supplementary Material I).
Arginine deprivation affects cell morphology
To establish whether and how single amino acid depriva-
tion affects cell morphology, cells cultured in -Arg, -Lys or 
control media were stained with phalloidin to visualize fila-
mentous actin. The staining was also performed for freshly 
isolated rat primary culture glia cells.
There were no evident changes in glia cells neither in 
morphology nor in actin cytoskeleton organization after 
48-h arginine or lysine starvation with respect to control 
cells (Fig. 2a, insets). Of note, though cultured glia cells 
did not resemble an astrocyte-like morphology they still 
expressed GFAP (not shown).
However, there was a significant effect of 48-h arginine 
deprivation on the morphology of the examined glioblas-
toma cells (Fig. 2b–d), which persisted during 144 h of the 
treatment (not shown). The majority of arginine-deprived 
U251 cells became elongated and did not form wide lamel-
lipodium, visible in control and -Lys cells (Fig. 2b, insets). 
Scanning electron micrographs confirmed prominent 
changes in morphology and in the leading edge formation 
in -Arg cells but not in control and -Lys cells (Fig. 2c). 
Staining for actin filaments revealed less stress fibers and 
less intensive cortical actin staining in -Arg cells when 
compared to -Lys and control cells. Similar characteristic 
changes in microfilament organization were also observed 
in U87 cells (Fig. 2d, insets).
The observed specific effect of arginine deprivation on 
cell morphology was reversible since re-supplementation 
of arginine resulted in fast restoration of U251 cells to 
Fig. 1  Effect of arginine 
deprivation on glioblastoma 
cells. a Cell growth of U251 
(upper panel) and U87 (lower 
panel) cells cultivated in 
control, -Arg, -Lys and condi-
tions. b U251 cell viability 
assessed under deprivation and 
re-supplementation conditions, 
as indicated. Upper and lower 
panels, arginine and lysine re-
supplementation, respectively. 
100 %, the number of the viable 
cells at time 0. Data in a and 
b are means ± SD; *** and 
*Statistical relevance p < 0.001 
and p < 0.05, respectively
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Fig. 2  Arginine depriva-
tion affects morphology of 
glioblastoma but not glia cells. 
a, b, d Rat glia, U251 and 
U87 cells stained with Alexa 
488-phalloidin, respectively. 
c Micrographs of U251 cells 
attained with scanning electron 
microscope. Insets in a, b and 
d ~2–3× magnification of the 
marked areas. Bars, in a, b and 
d 50 μm, and in c 10 μm. e 
U251 cells stained with Alexa 
488-phalloidin before and after 
re-supplementation with Arg or 
Lys up to 0.4 and 0.8 mM con-
centration, respectively. Arrows 
point to lamellipodia, arrow-
heads point to elongated cells
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the control phenotype (Fig. 2e). The reversion was visible 
already 3 h after adding arginine (Electronic Supplemen-
tary Materials II–IV).
Arginine deprivation inhibits cell motility
The changes in the cytoskeleton organization suggest that 
arginine deprivation could affect glioblastoma cell motil-
ity. Therefore, we assessed random cell motility without 
external chemotactic stimuli using time-lapse micros-
copy that allowed assessment of migration rate as well as 
mean distance for individual cells as well as to observe the 
morphology of motile cells (Fig. 3; Kouvroukoglou et al. 
2000). Analysis of 10 randomly chosen cells from each 
experimental condition revealed that arginine deprivation 
dramatically decreased the cell speed and mean distance, 
and concomitantly affected morphology of migrating -Arg 
cells.
No significant effect of arginine or lysine depriva-
tion on glia cells was observed. Their migration rates in 
the control, -Arg or -Lys condition were 0.023, 0.020 and 
0.021 μm/min, respectively. Also, for 48 h they moved for 
the distance of 68 μm (control cells), 59 μm (-Arg cells) 
and 62 μm (-Lys cells).
The inhibitory effect of arginine deprivation on glioblas-
toma cell motility was confirmed by a wound healing assay 
(Electronic Supplementary Material V).
Arginine deprivation impairs cell invasiveness
Since arginine deprivation inhibited cell motility, we tested 
whether arginine deficit could impair cell invasiveness. 
Experiments were performed using a Transwell filter sys-
tem in the presence or absence of Matrigel as well as using 
organotypic brain slices (Fig. 4). As shown in Fig. 4a, -Arg 
cells passed through the filter less efficiently, as without 
Matrigel—with respect to control—only ~15 and ~30 % 
of -Arg U251 and U87 cells, respectively, were found after 
6 h on the trans side of the filter. In -Lys conditions ~72 
and ~64 % of U87 and U251 cells, respectively, migrated 
through the filter.
In the presence of Matrigel (Fig. 4b), in -Arg condition 
only ~15 and ~28 % of U251 and U87 cells, respectively, 
were found on the filter’s trans side with respect to control 
conditions. For -Lys conditions these values were ~95 and 
~108 % for U251 and U87 cells, respectively.
Similar observation was made for LNB-229 glioblastoma 
cells that are known to generate invasive tumors (Hlavaty 
et al. 2011). In -Arg conditions only ~5 % migrated through 
the Matrigel-coated filter while in -Lys conditions the num-
ber was similar to that of control cells (Fig. 4c).
Also, to reveal that arginine deprivation could affect 
glioblastoma cell invasiveness in vivo we used rat brain 
organotypic slices of neonatal and adult animals that were 
uniformly overlayed with GFP-transfected U251 cells, 
which prior to the experiment were cultured for 24 h in 
-Arg and -Lys as well as in control media (Fig. 4d). After 
24-h co-culture in the examined conditions, the brain slices 
were washed with PBS and after fixation the amount of 
fluorescent cells within a slice (i.e. the central planar sec-
tion) was estimated by means of confocal microscopy. As 
shown for E13 brain slices (Fig. 4d), -Arg cells did not pen-
etrate the tissue as effectively as the control and -Lys cells. 
Quantification of images obtained for both E13 and adult 
brains slices revealed that with respect to the control cells 
only ~15 % of -Arg cells were found within the slices of 
both neonatal and mature brains. These numbers were ~115 
and ~80 % for -Lys cells.
Thus, the inhibition of glioblastoma cell invasiveness 
appears to be a specific arginine-related effect.
Arginine deprivation affects cell adhesion
The observed changes in the arginine-deprived glioblas-
toma cell morphology, migration and invasiveness suggest 
alterations in cell adhesion. Adhesion was tested as cell 
attachment to the surface (heterotypic adhesion, Fig. 5a, b) 
or cell–cell interactions (homotypic adhesion; Fig. 5c).
To assess the adhesive structure formation, U251 cells 
were immunostained for vinculin and talin, the focal con-
tact markers. Distribution of both proteins in -Arg cells 
was different from the control and -Lys counterparts as the 
fluorescence at the cell edges was less intensive (Fig. 5a, 
b). Quantification of vinculin-stained structures indicates 
that ~2.5× less adhesion contacts were formed in -Arg 
cells (starved for 48 h) in comparison with the control and 
-Lys cells (Fig. 5a, right panel). However, arginine depriva-
tion did not significantly affect the expression of proteins 
involved in cell adhesion as their levels in -Arg cells did not 
change with respect to control and -Lys cells as revealed by 
immunodetection for talin, vinculin, CD44 and E-cadherin 
(see Fig. 5b, right panel).
For the assessment of clonogenic potential, U251 cells 
were cultured on soft agar for 24 h, and the amount of 
aggregates with 2–10, 11–50 and >50 cells was quantified 
(Fig. 5c). -Arg cells formed significantly fewer aggregates 
with high cell numbers (~20 % of the >50-cell aggregates 
relative to control conditions and to 60 % for -Lys cells).
The data indicate that arginine deprivation severely 
impairs cell adhesion.
Arginine deprivation affects organization of actin 
cytoskeleton
The above described arginine deprivation-related effects 
could be evoked by the observed alterations in actin 
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cytoskeleton organization (see Fig. 2) and/or actin synthe-
sis. We addressed this supposition using U251 cells, which 
exhibited more pronounced morphological alterations upon 
arginine deprivation.
Western blotting showed no significant difference in the 
overall content of β- and γ-actins as well as of β-tubulin in 
the lysates of -Arg, -Lys and control cells, indicating that 
arginine deprivation did not affect total actin level (Fig. 5d).
Fig. 3  Arginine deprivation 
impairs cell motility. a, b 
Migration tracks of U251 and 
U87 cells, respectively. Upper 
panels in a and b tracks of 10 
randomly chosen cells; center 
panels images of migrating 
cells, and lower panels values 
of migration rate and mean 
distance based on tracks shown 
in upper panels. Values are 
means ± SD. ***Statistical 
relevance p < 0.001
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Fig. 4  Arginine deprivation impairs cell migration and invasiveness. 
Transwell filters not covered (a), and covered with Matrigel (b, c) 
were used for analyses. Upper and lower panels in a and b images 
of U251 and U87 stained cells, respectively, taken on the filter trans 
side. c Images of LN-229 cells, analyzed as in b. Analyses were per-
formed for three independent experiments run in duplicates. d Images 
of GFP-expressing U251 cells found within the E13 organotypic 
brain slice. The images represent the confocal 12.3-μm z-section of 
the planar center of brain slices. Right panel the quantification of 
GFP-expressing U251 cells within the confocal center of the slice per 
view area. The quantitative data in a–d are presented as % of control. 
Values are means ± SD. ***Statistical relevance p < 0.001
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To assess actin filament content, we also employed flow 
cytometry. Cells were stained with Alexa-conjugated phal-
loidin and the fluorescence intensity spectra of 10,000 cells 
were collected. As shown in Fig. 5e, the mean fluorescence 
intensity (presented as GeoMean) was evidently smaller 
in -Arg cells than in -Lys and control cells, indicating 
that -Arg cells contained significantly less actin filaments. 
As expected, there was practically no difference in the 
GeoMean values for rat glia cultured in the examined con-
ditions (Electronic Supplementary Material VI).
Since there is no dramatic difference in binding of phal-
loidin to mammalian actin isoforms (Allen et al. 1996), 
we performed a sedimentation assay to characterize β- or 
γ-actins content by Western blotting in the supernatant 
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(containing monomeric G-actin and/or small oligomers) 
and pellet (containing filamentous F-actin and/or actin bun-
dles). Densitometric analysis of the supernatant and pellet 
fractions is presented in Fig. 5f. We observed higher con-
tent of β-actin in the supernatant fraction of -Arg cells in 
comparison with -Lys and control cells. Contrary to that, 
there was no pronounced difference in the γ-actin frac-
tion content. Similar observation was made for lysates, 
which prior to ultracentrifugation were pre-incubated with 
phalloidin to prevent possible filament disassembly during 
sample processing (Fig. 5g).
Analogous analysis of microtubule organization with 
anti-β-tubulin antibodies revealed no evident difference in 
the microtubule versus tubulin dimer ratio of samples from 
-Arg, -Lys and control cells (Fig. 5h).
Arginine deprivation impairs β-actin arginylation
The impact of arginine deprivation on cell migration and 
cytoskeleton organization resembled to some extent the 
findings in mouse cells with knockdown or treated with 
inhibitors of arginyl transferase 1 (Ate1), an enzyme 
responsible for protein arginylation (Saha et al. 2012; Kara-
kozova et al. 2006). This implies that arginine deprivation 
could affect β-actin arginylation. To verify this hypothesis, 
we performed 2D electrophoresis and mass spectrometry 
analysis (Fig. 6).
2D electrophoresis revealed a difference in the actin 
isoelectric pattern between the analyzed samples (Fig. 6a). 
Out of three major spots detected by anti-actin antibody in 
control and -Lys cells, only two with more acidic pI were 
seen in -Arg cells. This suggests changes in posttransla-
tional modification of actin pattern, possibly due to impair-
ment in β-actin arginylation.
MS^E data analysis with ProteinLynx Global Server 
2.4 software allowed identification of arginylated N-ter-
minal peptide. With this approach, we found Arg residue 
on the N-terminus of Asp2 and not on Asp3 of the β-actin 
Fig. 6  Arginine deprivation impairs β-actin arginylation. a 2D-elec-
trophoresis of cell lysates probed with anti-actin antibody. Arrows 
point to major actin isoelectric forms. “−” and “+”, lower and higher 
pH, respectively. b Deconvoluted MS/MS spectrum of the N-termi-
nally arginylated β-actin peptide, with carbamidomethyl modification 
on cysteine (MH+ 1,935.89 Da, mass error 9.14 ppm). ProteinLynx 
Global Server software assigned following 15 fragment products 
of precursor peptide to the observed spectrum (mass error in ppm 
given in brackets): y2 (−1.4022), y3 (−2.3098), y5 (0.8842), y6 
(1.8187), y8 (−0.1555), y10 (0.0295), y11 (−1.0726), y12 (0.4542), 
y13 (−0.5259), b12 (8.5818), y8-H2O (0.1441), y9-H2O (−4.6865), 
y10-H2O (24.4993), y7-NH3 (5.1754), y13-NH3 (11.683). Inset in b, 
β-actin arginylation in -Arg and -Lys cells as the % of β-actin argi-
nylation in control cells. Values are means ± SD. ***Statistical rel-
evance p < 0.001
Fig. 5  Arginine deprivation affects cell adhesion and β-actin organi-
zation. a, b U251 cells stained with anti-vinculin and anti-talin anti-
body, respectively. Graph in a, quantification of vinculin-containing 
structures visualized in confocal microscope after 48-h cultivation 
in the examined conditions; 20 cells were analyzed. Right panel in 
b western blot analysis of cell lysates for the presence of talin vin-
culin, CD44 and E-cadherin in U251 cell after 48-h cultivation in the 
examined conditions. c Assessment of homotypic adhesion by analy-
sis of the formed cell aggregates. d Western blots of total cell lysates 
probed with anti-β- and γ-actin, and anti-β-tubulin antibodies. e Flow 
cytometry analyses of cells stained with Alexa 488-conjugated phal-
loidin. Arrows point to the fluorescence peak of each experimental 
condition. This is a representative result from four independent exper-
iments. Right panel quantitative analysis where 100 % is GeoMean 
value of control cells. The data in e are based on four independent 
experiments. f Quantitative analyses of β- and γ-actin isoforms con-
tent in the pellet (F-actin, upper bar) and supernatant (G-actin, lower 
bar) fractions. g The same as in f but in the presence of phalloidin. 
h Quantitative analysis of β-tubulin content performed as in f, where 
lower and upper bars correspond to tubulin dimers and microtubules, 
respectively. Data in f–h are from three independent experiments run 
in duplicates. Data in a, c, e and f–h are means ± SD. *, **, ***Sta-
tistical relevance p < 0.05, p < 0.01 and p < 0.001, respectively
◀
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sequence (RDDIAALVVDNGSGMCK), and its assign-
ment to a mass peak on chromatogram based on the meas-
ured parent peptide mass and its corresponding fragment 
mass spectrum (Fig. 6b). The peptide coverage for β-actin 
molecule was between 78 and 88 % depending on the run.
To compare the extent of N-terminal protein arginylation 
between the control and -Arg or -Lys samples, the chroma-
tograms for masses (chosen ion intensities as measured by 
the instrument, versus scan numbers) of non-fragmented 
arginylated N-terminal peptide and for five randomly 
selected peptides from the digest were integrated and the 
arginylation extent was established as described in Meth-
ods section. The extent of actin arginylation for control 
samples (n = 4) was set as 100 %, and for -Arg samples 
was calculated as 64 ± 8 % (n = 4) and for -Lys samples 
as 84 ± 11 % (n = 3) (Fig. 6b, inset). Therefore these data 
confirm a more pronounced relative decrease in arginylated 
β-actin in the arginine-deprived cells.
Discussion
A number of studies evaluated arginine deprivation-based 
strategy as potential anti-cancer therapy, which allows to 
control growth of tumors deficient in arginine biosynthesis 
(reviewed in Delage et al. 2010; Feun et al. 2008; Wheat-
ley 2004; Yoon et al. 2013). Many cultured tumor cells are 
highly sensitive to arginine deprivation, an essential amino 
acid for malignant cells in vitro (Bobak et al. 2010), and 
often exhibit progressive decrease in viability and signs of 
apoptosis (Delage et al. 2010). Such response, however, 
does not necessarily translates to 3D cultures of tumor 
cells (Vynnytska-Myronovska et al. 2012), or to in vivo, 
as revealed by clinical trials with recombinant arginine-
degrading enzymes (Glazer et al. 2010; Yang et al. 2010; 
Yau et al. 2013).
Surprisingly up to now there were no reports on the 
mechanisms of arginine deprivation on malignant cells 
metastatic potential. Also, effect of arginine deprivation 
on brain physiology was not studied, though its prominent 
role in brain development and degeneration was shown 
(Yi et al. 2009). However, if the problem of in vivo argi-
nine conversion from its precursors, primarily citrulline, is 
resolved (Syed et al. 2013), brain cancers can be potential 
objects of arginine deprivation-based therapy because such 
a metabolic approach is not dependent on permeability of 
the brain-blood barrier, which is often a concern for brain 
tumors chemotherapy.
We report for the first time that arginine deprivation 
strongly impairs motility, migration and invasiveness as 
well as hetero- and homotypic adhesion of human glioblas-
toma cell lines. We showed that these effects were associ-
ated with changes in the actin cytoskeleton organization 
that could result from depletion of β-actin arginylation. The 
observed phenomena were arginine-specific as deprivation 
for lysine, also a positively charged essential amino acid, 
caused significantly milder effects. Lysine deprivation was 
chosen as an experimental control to discern between the 
general effects of a single essential amino acid starvation 
and those specific only for arginine deprivation.
Although starvation for arginine abrogated cell growth, 
decreased in a time-dependent manner cell viability 
and altered cytoskeletal organization; these effects were 
reversed upon restoring optimal growth conditions by argi-
nine re-supplementation. Therefore, being relatively resist-
ant to arginine deprivation, three glioblastoma cell lines 
served in our hands as useful and informative models for 
elucidating and dissecting possible specific effects of argi-
nine withdrawal relevant to metastatic potential of malig-
nant cells. Importantly, we did not observe any evident 
effect of arginine or lysine starvation on primary rat glia 
cell morphology, migration and microfilament organization.
Impairment of migration and adhesion is predominantly 
due to aberrations in actin cytoskeleton organization (Pollard 
and Cooper 2009). Using several independent techniques, 
we demonstrated that changes observed in glioblastoma cell 
morphology and behavior under arginine deprivation were 
associated with actin cytoskeleton remodeling but not with 
overall actin level. Also, we showed that arginine depriva-
tion-evoked decrease in filament content concerned β-actin 
but not γ-actin isoform, and demonstrated that arginine dep-
rivation diminished the extent of β-actin arginylation, a post-
translational modification mediated by arginyltransferase 
(Ate1). Arginylation of this actin isoform was already shown 
to be crucial for cell migration and cardiomyocyte contractil-
ity (Terman and Kashina 2013; Saha et al. 2012; Kurosaka 
et al. 2012). It is plausible that arginylation of other cytoskel-
etal proteins could be also affected in -Arg cells since as it 
was previously reported numerous actin-binding proteins, 
including talin had been found to be arginylated (Saha et al. 
2010; Wong et al. 2007; Zhang et al. 2012). Thus it is pos-
sible that the observed defects in adhesive structure forma-
tion could be also related to arginylation of talin and/or other 
protein(s) involved in adhesion complex formation and cell–
cell interactions (Wong et al. 2007; Zhang et al. 2012).
Summarizing, we showed for the first time that arginine 
deprivation-dependent effects on glioblastoma cell mor-
phology, adhesion, migration and invasiveness were associ-
ated with specific changes in actin cytoskeleton organiza-
tion caused by decrease in β-actin arginylation. Since these 
effects concerned malignant but not untransformed glia 
cells, one may consider arginine deprivation-based strategy, 
possibly rationally designed combinational regimen for the 
control and treatment of brain tumors. Further studies are 
certainly needed to fully understand molecular mechanisms 
underlying these effects, and whether they also take place in 
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other tumors. Recent findings that intrinsic amino acid catab-
olism is involved in determining glioma aggressiveness in 
vivo (Tönjes et al. 2013) and that some brain tumors are defi-
cient in arginine biosynthesis (Syed et al. 2013) draw further 
interest to the development of metabolic therapies against 
these highly malignant tumors. However, it has also to be 
experimentally addressed whether and how prolonged argi-
nine deprivation affects functioning of immune system and 
brain physiology, in particular. This is an important aspect 
especially in the light of the data indicating that depletion of 
arginine has a differential impact on the activation and func-
tions of T cells and macrophages (Choi et al. 2009).
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